Wire · opportunities
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 19 August 2026 · Fusion42 review
The FDA has granted fast track designation to PLN-101095 in combination with pembrolizumab for treating solid tumors resistant to immune checkpoint inhibitors, advancing the ongoing phase 1a/1b FORTIFY trial.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech company can capitalise on the accelerated FDA pathway for ICI-resistant solid tumor therapies by prioritising PLN-101095 clinical data advancement. The fast track opens the door for earlier patient access and funding opportunities ahead of competitors.
◆ Coverage
1 source · 19 Aug 2026
◆ Related on Wire
◆ Topics
Biotechfda-fast-trackoncologyimmune-checkpoint-inhibitorspln-101095pembrolizumab